Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

Table 5 Toxicity profiles for the initial gefitinib and 2nd EGFR-TKI treatments. Adverse events were evaluated according to Common Terminology Criteria for Adverse Events of the National Cancer Institute (version 3.0).

Case	Initial gefitinib	2^nd EGFR-TKI
1	-	Rash G2
2	Rash G2	-
3	-	-
4	Rash G2, Liver G1, Diarrhea G2	Rash G1, Diarrhea G1
5	Rash G1	Rash G2
6	Diarrhea G2, Taste alteration G2	Rash G1, Diarrhea G1
7	Rash G2, Liver G3	Rash G2, Liver G3
8	Rash G2	Liver G2
9	Rash G1, Nail G1, Nausea G1	Rash G1
10	Liver G1	-
11	-	Rash G1, Diarrhea G1

G, grade; Liver, serum glutamic pyruvic transminase, serum glutamic oxaloacetic transaminase and γ-glutamyltranspeptidase.

ISSN: 1471-2407